CDIO (Cardio Diagnostics Holdings Inc. Common stock) Stock Analysis - News

Cardio Diagnostics Holdings Inc. Common stock (CDIO) is a publicly traded Healthcare sector company. As of May 19, 2026, CDIO trades at $1.39 with a market cap of $4.11M and a P/E ratio of -0.38. CDIO moved -1.44% today. Year to date, CDIO is -51.76%; over the trailing twelve months it is -69.00%. Its 52-week range spans $0.97 to $53.10. Rallies surfaces CDIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in CDIO news today?

Cardio Diagnostics Launches AI-Powered Epi+Gen CHD and PrecisionCHD Tests: Cardio Diagnostics Holdings is developing a suite of AI-driven clinical, population health and biopharma solutions that integrate genetic and epigenetic biomarkers for earlier detection and personalized management of preventable cardiovascular disease. The platform currently includes Epi+Gen CHD(TM) and PrecisionCHD(TM) blood-based tests aimed at identifying key risk factors in at-risk populations.

CDIO Key Metrics

Key financial metrics for CDIO
MetricValue
Price$1.39
Market Cap$4.11M
P/E Ratio-0.38
EPS$-3.71
Dividend Yield0.00%
52-Week High$53.10
52-Week Low$0.97
Volume71.48K
Avg Volume0
Revenue (TTM)$14.82K
Net Income$-6.50M
Gross Margin0.00%

Latest CDIO News

Recent CDIO Insider Trades

  • Dogan Timur bought 68.97K (~$20.00K) on Sep 6, 2024.
  • Dogan Meeshanthini bought 68.97K (~$20.00K) on Sep 6, 2024.
  • Philibert Robert bought 26.61K (~$7.64K) on Sep 6, 2024.

CDIO Analyst Consensus

CDIO analyst coverage data. Average price target: $0.00.

Common questions about CDIO

What changed in CDIO news today?
Cardio Diagnostics Launches AI-Powered Epi+Gen CHD and PrecisionCHD Tests: Cardio Diagnostics Holdings is developing a suite of AI-driven clinical, population health and biopharma solutions that integrate genetic and epigenetic biomarkers for earlier detection and personalized management of preventable cardiovascular disease. The platform currently includes Epi+Gen CHD(TM) and PrecisionCHD(TM) blood-based tests aimed at identifying key risk factors in at-risk populations.
Does Rallies summarize CDIO news?
Yes. Rallies summarizes CDIO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CDIO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CDIO. It does not provide personalized investment advice.
CDIO

CDIO